Evaluate AUPH stock safety — financial health, volatility, institutional backing, and risk factors.

What are the risks of investing in AUPH? | Glauxie AI

Q: What are the risks of investing in AUPH?

Aurinia Pharmaceuticals Inc. (AUPH) operates in the Biotechnology industry (Healthcare sector). The company is led by CEO Kevin C. Tang. Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States... Employees: 128.

Q: How much debt does AUPH have?

Review AUPH total debt, debt-to-equity ratio, interest coverage, and leverage trends.

Q: Is AUPH a good long-term investment?

Evaluate AUPH as a long-term investment using fundamental scores, growth metrics, and risk assessment.

What are the risks of investing in AUPH?

🦉

Aurinia Pharmaceuticals Inc. (AUPH)

Company Overview

Sector / IndustryHealthcare / Biotechnology

CEOKevin C. Tang

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active...

Key Executives

Name	Title
Andrea Levin Christopher	Executive Director of Corporate Communications & Investor Relations
Eric Victory	Vice President of Corporate Development
Gregory F. Keenan	Senior VP & Chief Medical Officer
Joseph Miller	Chief Financial Officer
Kevin C. Tang	Chairman & CEO
Lucy Shieh	Vice President of Human Resources & Operations

Financial Health

Risk Assessment

Weather Score0/100

RegimeN/A

AUPH Profile Financials

Is AUPH stock safe? How much debt does AUPH have? Is AUPH a good long-term investment?